Halcion

Halcion is a prescription medication whose active ingredient is triazolam, a benzodiazepine classified as a sedative‑hypnotic. It is supplied in oral tablet form and is marketed in the European Union. Triazolam works as a positive allosteric modulator of the GABAA receptor, enhancing the inhibitory action of GABA in the central nervous system. Halcion is regulated as a prescription‑only product and is intended for short‑term use under medical supervision.

Halcion (triazolam) is primarily prescribed for the short‑term management of insomnia when rapid onset of sleep is required.

- Short‑term treatment of difficulty falling asleep, helping patients achieve sleep onset within 30 minutes. - Use in individuals experiencing transient sleep‑initiation problems that are not resolved by behavioral interventions. - May be considered when non‑pharmacologic sleep hygiene measures have been insufficient to improve sleep latency. - Therapy is generally limited to a few consecutive nights (typically ≤7 days) to minimize tolerance and dependence. - Prescribed under physician supervision for adult patients with acute insomnia, not for chronic sleep disorders.

The side‑effect profile of triazolam reflects its benzodiazepine class and includes both frequent, mild reactions and less common, serious events.

Common: - Drowsiness or fatigue during the day. - Light‑headedness or dizziness. - Impaired coordination or balance. - Memory disturbances such as anterograde amnesia for events after dosing. - Slurred speech or difficulty concentrating. - Gastrointestinal upset such as nausea or abdominal discomfort.

Serious: - Paradoxical reactions including agitation, aggression, or hallucinations. - Respiratory depression, especially when combined with other central nervous system depressants.

Because triazolam is a potent short‑acting benzodiazepine, several precautions should be observed before and during therapy.

- Assess for a history of substance abuse or dependence before initiating treatment. - Avoid use in patients with severe respiratory disorders such as chronic obstructive pulmonary disease. - Limit duration to the shortest effective period to reduce risk of tolerance and withdrawal. - Counsel patients about potential next‑day impairment and advise against operating machinery or driving. - Use caution in the elderly, who may be more susceptible to sedation and falls. - Review pregnancy status; safety in pregnancy has not been established. - Discontinue gradually under medical guidance to prevent rebound insomnia.

Triazolam can interact with other medications that affect the central nervous system or alter its metabolism.

Avoid: - Other benzodiazepines, barbiturates, or sleep‑inducing agents, which can cause additive sedation. - Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or clarithromycin, which may increase triazolam levels. - Alcohol or illicit substances that depress the central nervous system, raising the risk of respiratory depression.

Use with caution: - Antidepressants that affect serotonin or GABA pathways, such as selective serotonin reuptake inhibitors, may enhance sedation. - Opioid analgesics, because combined use can potentiate respiratory depression and profound sedation.